AT THE COMPANY AT THE FINANCIAL RELATIONS BOARD
Robert V. Toni, President & CEO
J. Blount Swain, CFO
CLOSURE Medical Corporation
(919) 876-7800
For General Info: Paul G. Henning (212) 661-8030
For Analyst Info: Brian Gill (212) 661-8030
For Media Info: Deanne Eagle (212) 661-8030

FOR IMMEDIATE RELEASE: August 4, 1999

CLOSURE MEDICAL CORPORATION AWARDED U.S. PATENT
RELEVANT TO DERMABOND*

Raleigh, NC, August 4, 1999-- CLOSURE Medical Corporation (Nasdaq: CLSR), a medical tissue cohesive products company announced today that it has been awarded its first United States Patent relevant to its lead product, DERMABOND Topical Skin Adhesive. U.S. Patent No. 5,928,611, entitled Impregnated Applicator Tip, was issued on July 27, 1999.

The invention covered in this patent capitalizes on the ability of our adhesive technology to be manipulated in a manner that enhances product performance by controlling the setting time and extending the shelf life of the material, said Debra L. Pawl, Vice President and General Counsel.

This invention represents an exciting new capability to modify product characteristics for synthetic monomer materials, such as octyl cyanoacrylates, and we fully expect to continue to exploit this breakthrough in new product development projects, added J. Blount Swain, Chief Financial Officer. DERMABOND Topical Skin Adhesive is marketed by Ethicon, Inc., a subsidiary of Johnson & Johnson (NYSE:JNJ), under an exclusive worldwide supply and distribution agreement.

CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina, develops, manufactures and commercializes medical tissue cohesive products based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable tissue cohesive products may be used to replace sutures and staples for certain topical wound closure applications, while its absorbable tissue cohesive products can potentially be used as tissue cohesives for internal wound closure and management. Currently marketed nonabsorbable tissue cohesive products include DERMABOND topical skin adhesive, which is used to replace sutures and staples for closure of certain lacerations and incisions, OCTYLDENT® cohesive, which is used as an adjunct in the treatment of adult periodontal disease; and NEXABAND® topical cohesives, a family of products used in veterinary wound closure and management.

* DERMABOND is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL, OCTYLDENT and NEXABAND are all trademarks of CLOSURE Medical Corporation.

To receive CLOSURE’s latest news release and other corporate documents via fax, at no cost, call 1-800-PRO-INFO. Use the Company’s ticker, CLSR. Or visit the Financial Relations Board's website at www.frbinc.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company products; the progress of its research and deveopment programs for future nonabsorbable and absorbable products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 1998 filed with the Securities and Exchange Commission.